Once again, the spectre of Ebola has emerged from the equatorial forests, and the usual panic begins. But this time, something is different. Three vaccine candidates have entered the race, and remarkably, British scientists are leading the trial.
One might ask, why does this feel like a rerun of a tired series? Because it is. We have seen this before: the outbreak, the scramble for a cure, the media frenzy, and then the quiet subsiding until the next crisis.
The fall of Rome was not a single event but a series of failures masked by temporary victories. Our modern pharmaceutical responses mimic this pattern: heroic efforts that obscure the deeper rot of systemic neglect. The British involvement is commendable, yet it cannot hide the fact that we are perpetually reacting rather than preventing.
We pour billions into vaccines after the horse has bolted, while the stable doors of global health infrastructure remain flimsy. This is not a triumph of science; it is a admission of our collective intellectual decadence. We celebrate the race, but we ignore the fact that we are running in circles.
